Whalesbook
Dr. Reddy's India Sales Rebound Sharply
Dr. Reddy's Indian operations achieved a significant comeback in fiscal year 2026, with fourth-quarter sales jumping 20% year-on-year. This growth substantially outpaced the industry, signaling a successful recovery. CFO M.V. Narasimham stated that strategic changes, such as focusing the portfolio and improving productivity, were key to this turnaround. The India business now represents a solid 18-19% of the company's total revenue, offering stability. New product launches, price adjustments, and higher sales volumes fueled this resurgence.
Focus on Chronic Therapies and Productivity
Dr. Reddy's new Indian strategy emphasizes innovative and chronic therapy products. While the overall Indian Pharmaceutical Market (IPM) saw chronic therapies grow 14.2% by April 2026, Dr. Reddy's chronic segment revenue is about one-fifth of its India sales. Focusing on chronic care, like diabetes and heart treatments, is vital for steady, predictable revenue streams. The company also boosted operational efficiency, raising average monthly revenue per representative (PCPM) to an estimated ₹6.6-7 lakh. This productivity push aims to increase sales without a proportional rise in headcount, improving profitability in a competitive market. Leadership shifts and focus on key areas supported this commercial plan.
Market Rank Improves, But Chronic Gap Remains
These efforts have moved Dr. Reddy's up one spot in the Indian pharmaceutical market ranking to ninth on a quarterly basis. However, this rise masks a significant structural challenge. Analysts suggest Dr. Reddy's struggle to reach the top five in the IPM is due to its limited presence in the fast-growing chronic therapy segment. The IPM is forecast to grow 9-10% in FY27, but the chronic segment, which sees higher growth and patient adherence, offers greater long-term revenue potential. Dr. Reddy's recognizes this gap and is pursuing both new product launches and possible acquisitions to strengthen its chronic offerings.
Challenges: Low Chronic Share, Margin Pressure
Despite the turnaround story, a critical vulnerability persists: Dr. Reddy's limited share in India's chronic therapy segment. Chronic treatments make up over 40% of the total Indian Pharmaceutical Market (IPM), but Dr. Reddy's chronic business is only about one-fifth of its domestic sales. This limits its ability to compete effectively against peers like Sun Pharma, a major player in specialty medicines, and Cipla, a strong contender in key therapeutic areas. Additionally, Q4 FY26 saw adjusted EBITDA margins drop to 15.2%. This was affected by one-off items, including a ₹453 crore shelf-stock adjustment for lenalidomide sales and R&D impairments. While a weaker rupee provided currency benefits, it didn't fully cover the domestic chronic care gap. Some analysts remain cautious; Kotak Institutional Equities kept a 'Reduce' rating and a ₹1,175.00 price target, pointing to margin issues and reliance on specific launches like Semaglutide (Canada) and Abatacept (US) for future growth.
Future Growth Hinges on Chronic Strategy
Looking ahead, Dr. Reddy's plans to build on its recent domestic growth. The company intends to expand its chronic therapy products and seek acquisitions to strengthen this area. Integrating global assets and specialty products should further diversify revenue. The Semaglutide launch is expected to contribute to growth, though the company is not solely reliant on it. The Indian pharmaceutical market is projected to grow 9-10% in FY27, driven by price increases, new products, domestic demand, and the growing CDMO sector. Dr. Reddy's success will depend on effectively bridging the chronic therapy gap and sustaining operational efficiencies amid intense competition.